Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets ...

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...

In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known ...

The United States Food and Drug Administration (FDA) has approved the weight-loss drug Tirzepatide — sold by the brand name ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly blockbuster drugs ...

We recently compiled a list of the 10 Stocks That Will Make You Rich In 2025. In this article, we are going to take a look at ...

He knows the drug works but said there were challenges in getting TGA approval. Self-injectable medications such as ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...